Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254051 | 0.83 | POLB (0.54) | PKMPOLBL3MBTL1GAAALDH1A1 | |
| SCHEMBL28018957 | 0.82 | PKM (0.50) | PKMPOLBGAAALDH1A1LMNA | |
| SCHEMBL29956918 | 0.78 | POLB (0.46) | CA1CA2PKMPOLBGAA | |
| SCHEMBL1976805 | 0.75 | CA1 (0.50) | CA1CA2PKMPOLBL3MBTL1 | |
| SCHEMBL28977118 | 0.75 | AKR1C3 (0.56) | PKMPOLBGAAALDH1A1LMNA | |
| SCHEMBL19204884 | 0.74 | GAA (0.62) | PKMPOLBL3MBTL1GAAALDH1A1 | |
| SCHEMBL6582500 | 0.74 | GAA (0.54) | PKMPOLBL3MBTL1GAAALDH1A1 | |
| SCHEMBL4993025 | 0.73 | GRM4 (0.51) | CA1CA2PKMPOLBGAA | |
| SCHEMBL1826706 | 0.71 | CA1 (0.46) | CA1CA2PKMPOLBL3MBTL1 | |
| SCHEMBL24254288 | 0.71 | POLB (0.58) | PKMPOLBL3MBTL1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| EP-3356344-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Ltd (GB) | 2018-08-08 | — | — | EP | disclosed |
| CN-107162976-A | A kind of method for the 1 sulfonyl 1H pyrazoles for synthesizing substitution | 五邑大学 | 2017-09-15 | — | — | CN | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| WO-2005073198-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | WYETH (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0009998-B1 | PEROXYGEN CONTAINING COMPOSITIONS AND BLEACHING PROCESS | FMC Corporation (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4230591-A | Peroxygen bleaching and compositions therefor | FMC CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
| US-4207070-A | Peroxygen bleaching and compositions therefor | FMC CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | CA1 1872/4885CA2 1841/4885PKM 2074/4885 |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | CA1 4811/4885CA2 3591/4885PKM 790/4885 |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | CA1 1372/4885CA2 172/4885PKM 1823/4885 |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | CA1 1872/4885CA2 1841/4885PKM 2074/4885 |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | CA1 1372/4885CA2 172/4885PKM 1823/4885 |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | CA1 1872/4885CA2 1841/4885PKM 2074/4885 |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | IAPP, APP, CBR3 | CA1 410/4885CA2 820/4885PKM 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.